{"id":"W1996330154","doi":"10.1038/bjc.2012.319","title":"A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours","year":2012,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Aflibercept; Pemetrexed; Neutropenia; Internal medicine; Febrile neutropenia; Adverse effect; Cisplatin; Gastroenterology; Pharmacology; Bevacizumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001544675,0.001382591,0.002488256,0.0004987334,0.0003929184,0.001111041,0.0009233131,0.001075043,0.00243974],"category_scores_gemma":[0.001400993,0.0006971442,0.001104,0.0006949718,0.0009420422,0.0009303143,0.0004020427,0.004476612,0.000792529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001383847,"about_ca_system_score_gemma":0.001605855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006556613,"about_ca_topic_score_gemma":0.00117601,"domain_scores_codex":[0.999289,0.0002684659,0.0000479507,0.0001766901,0.0001024882,0.0001153595],"domain_scores_gemma":[0.9989738,0.0001313635,0.0002821167,0.000111588,0.00006744931,0.0004337316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5328284,0.1616621,0.01907967,0.001235252,0.00219898,0.0004827607,0.0009369241,0.005932955,0.1090124,0.0002554585,0.003482776,0.1628924],"study_design_scores_gemma":[0.365689,0.6017745,0.02154276,0.0000317614,0.000500768,0.0005901915,0.00006732165,0.001670524,0.00494843,0.0001562319,0.002995753,0.00003275737],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995593,0.001023543,0.0004668518,0.0001911041,0.00004990168,0.001631174,0.0002907375,0.0000484563,0.0007053044],"genre_scores_gemma":[0.9937478,0.0008851999,0.001726297,0.0004545408,0.00007882962,0.001594965,0.0007791417,0.00002262111,0.0007106629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002488256,"threshold_uncertainty_score":0.01004052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01515394302190588,"score_gpt":0.3460659373982292,"score_spread":0.3309119943763233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}